A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins

International Journal of Pharmaceutics

Volumn 358, Issue 1-2, 2008, Pages 159-167

  Sivadas, Neeraj ^a   O'Rourke, Desmond ^a   Tobin, Aoife ^a   Buckley, Vivienne ^a,c   Ramtoola, Zeibun ^a   Kelly, John G ^a   Hickey, Anthony J ^b   Cryan, Sally Ann ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Calu 3; Microparticles; Protein; Pulmonary drug delivery; Toxicity

Indexed keywords

ALGINIC ACID; BOVINE SERUM ALBUMIN; CHITOSAN; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; GELATIN; HYALURONIC ACID; HYDROXYPROPYLCELLULOSE; INTERLEUKIN 8; MANNIDEX; MANNITOL; MICROSPHERE; OVALBUMIN; POLYGLACTIN; POLYMER;

ADULT; AEROSOL; ARTICLE; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRY POWDER; ELECTRIC RESISTANCE; FLOW KINETICS; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; HUMAN; HUMAN CELL; IMMUNOGENICITY; INHALATIONAL DRUG ADMINISTRATION; LUNG TOXICITY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POWDER INHALER; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESPIRATORY EPITHELIUM; SPRAY DRYING;

ADMINISTRATION, INHALATION; AEROSOLS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DESICCATION; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; FLUORESCEIN; FLUORESCENT DYES; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYMERS; PROTEINS; TETRAZOLIUM SALTS; THIAZOLES; WATER;

EID: 44649091155     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.03.024     Document Type: Article

References (51)

1. Abe S., Takizawa H., Sugawara I., and Kudoh S. Diesel exhaust (DE)-induced cytokine expression in human bronchial epithelial cells: a study with a new cell exposure system to freshly generated DE in vitro. Am. J. Respir. Cell Mol. Biol. 22 (2000) 296-303
2. Atkinson K.J., and Rao R.K. Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions. Am. J. Physiol. Gastrointest Liver Physiol. 280 (2001) G1280-G1288
3. Bivas-Benita M., van Meijgaarden K.E., Franken K.L., Junginger H.E., Borchard G., Ottenhoff T.H., and Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22 (2004) 1609-1615
4. Blank F., Rothen-Rutishauser B.M., Schurch S., and Gehr P. An optimized in vitro model of the respiratory tract wall to study particle cell interactions. J. Aerosol. Med. 19 (2006) 392-405
5. Boer A.H.d., Grietje M., and Henderik W.F. Pulmonary drug delivery: delivery to and through the lung. In: Molema G., and Meijer D.K.F. (Eds). Drug Targeting Organ-Specific Strategies (2001), Wiley-VCH Verlag GmbH 53-88
6. Bosquillon C., Lombry C., Preat V., and Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control Rel. 70 (2001) 329-339
7. Chan H.K., Clark A., Gonda I., Mumenthaler M., and Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Respir. 14 (1997) 431-437
8. Cryan S.A. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 7 (2005) E20-E41
9. Dunne M., Corrigan I., and Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21 (2000) 1659-1668
10. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
11. Evans S.M., Blyth D.I., Wong T., Sanjar S., and West M.R. Decreased distribution of lung epithelial junction proteins after intratracheal antigen or lipopolysaccharide challenge: correlation with neutrophil influx and levels of BALF sE-cadherin. Am. J. Respir. Cell Mol. Biol. 27 (2002) 446-454
12. Fiegel J., Fu J., and Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J. Control Rel. 96 (2004) 411-423
13. Foster K.A., Avery M.L., Yazdanian M., and Audus K.L. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208 (2000) 1-11
14. Franz T.J. Percutaneous absorption on the relevance of in vitro data. J. Invest. Dermatol. 64 (1975) 190-195
15. Grainger C.I., Greenwell L.L., Lockley D.J., Martin G.P., and Forbes B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm. Respir. 23 (2006) 1482-1490
16. Gupta M., and Gupta A.K. In vitro cytotoxicity studies of hydrogel pullulan nanoparticles prepared by AOT/N-hexane micellar system. J. Pharm. Pharm. Sci. 7 (2004) 38-46
17. Gupta R.K., Chang A.C., Griffin P., Rivera R., Guo Y.Y., and Siber G.R. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine 15 (1997) 672-678
18. Hanes J., Dawson M., Har-el Y., Suh J., and Fiegel J. Gene delivery to the lung. In: Hickey A.J. (Ed). Pharmaceutical Inhalation Aerosol Technology (2003), Marcel Dekker, Inc., New York 489-539
19. Hinds W.C. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles (1999), John Wiley & Sons, New York
20. Huang Y., Yeh M., and Chiang C. Formulation factors in preparing BTM-chitosan microspheres by spray drying method. Int. J. Pharm. 242 (2002) 239-242
21. ICRP. International Commission on Radiological Protection (ICRP), Human respiratory tract model for radiological protection: A report of a Task Group of the International Commission on Radiological Protection, ICRP Publication 66 (1994), Pergamon Press, Oxford
22. Igartua M., Hernandez R.M., Esquisabel A., Gascon A.R., Calvo M.B., and Pedraz J.L. Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. Int. J. Pharm. 169 (1998) 45
23. Knebel J.W., Ritter D., and Aufderheide M. Exposure of human lung cells to native diesel motor exhaust-development of an optimized in vitro test strategy. Toxicol. In Vitro 16 (2002) 185-192
24. Kohn, J.B., Pulapura, S., Schwartz, A., Bahulekar, R., 2007. Polyarylates for drug delivery and tissue engineering, US Patent 7,271,234, 18 September.
25. Lamprecht A., Schafer U., and Lehr C.M. Structural analysis of microparticles by confocal laser scanning microscopy. AAPS Pharm. Sci. Tech. 1 (2000) E17
26. Leitner V.M., Guggi D., Krauland A.H., and Bernkop-Schnurch A. Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J. Control Rel. 100 (2004) 87-95
27. Mack G.S. Pfizer dumps Exubera. Nat. Biotechnol. 25 (2007) 1331-1332
28. Maugis D. On the contact and adhesion of rough surfaces. J. Adh. Sci. Technol. 10 (1996) 161-175
29. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., and Ikada Y. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 52 (2000) 611-617
30. Newhouse M.T., Hirst P.H., Duddu S.P., Walter Y.H., Tarara T.E., Clark A.R., and Weers J.G. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 124 (2003) 360-366
31. Newman S.P., and Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 96 (2002) 293-304
32. Okamoto H., Todo H., Lida K., and Danjo K. Dry powders for pulmonary delivery of peptides and proteins. KONA 20 (2002) 71-83
33. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19 (1996) 3-36
34. Patton J.S., and Platz R.M. (D) Routes of delivery: case studies: (2) Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8 (1992) 179
35. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta. Helv. 60 (1985) 110-111
36. Robledo R.F., Barber D.S., and Witten M.L. Modulation of bronchial epithelial cell barrier function by in vitro jet propulsion fuel 8 exposure. Toxicol. Sci. 51 (1999) 119-125
37. Sakagami M., Kinoshita W., Sakon K., Sato J., and Makino Y. Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J. Control Rel. 80 (2002) 207-218
38. Sakagami M., Sakon K., Kinoshita W., and Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J. Control Rel. 77 (2001) 117-129
39. Sanjar S., and Matthews J. Treating systemic diseases via the lung. J. Aerosol. Med. 14 (2001) S51-S58
40. Scheuch G., Kohlhaeufl M.J., Brand P., and Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 58 (2006) 996-1008
41. Sethuraman V.V., and Hickey A.J. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS Pharm. Sci. Tech. 3 (2002) E28
42. Sham J.O., Zhang Y., Finlay W.H., Roa W.H., and Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 269 (2004) 457-467
43. Smith J., Wood E., and Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm. Respir. 21 (2004) 43-49
44. Suarez S., O'Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., and Hickey A.J. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Respir. 18 (2001) 1315-1319
45. Sujja-areevath J., Munday D.L., Cox P.J., and Khan K.A. Relationship between swelling, erosion and drug release in hydrophillic natural gum mini-matrix formulations. Eur. J. Pharm. Sci. 6 (1998) 207
46. Surendrakumar K., Martyn G.P., Hodgers E.C., Jansen M., and Blair J.A. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control Rel. 91 (2003) 385-394
47. USP, 2000. Aerosols, Metered Dose Inhalers, and Dry Powder Inhalers. United States Pharmacopoiea, USP 24, NF 19, 1895-1912.
48. Widdicombe J.H. Volume of airway surface liquid in health and disease. Am. J. Respir. Crit. Care Med. 165 (2002) 1566
49. Witschi C., and Mrsny R.J. In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery. Pharm. Respir. 16 (1999) 382-390
50. Zahoor A., Sharma S., and Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26 (2005) 298
51. Zeng X.M., Martin G.P., and Marriott C. Preparation and in vitro evaluation of tetrandrine-entrapped albumin microspheres as an inhaled drug delivery system. Eur. J. Pharm. Sci. 3 (1995) 87